KNT-127
KNT-127 is a D1 receptor partial agonist that is under investigation for the treatment of schizophrenia and Parkinson's disease. It is being developed by Kyowa Hakko Kirin, a Japanese pharmaceutical company.
History[edit | edit source]
KNT-127 was first synthesized by researchers at Kyowa Hakko Kirin. The compound was identified as a potential therapeutic agent due to its unique pharmacological profile. It is a partial agonist at the D1 receptor, meaning it can both activate and inhibit this receptor depending on the physiological context. This makes it a promising candidate for the treatment of disorders characterized by dysregulated dopamine signaling, such as schizophrenia and Parkinson's disease.
Pharmacology[edit | edit source]
KNT-127 is a partial agonist at the D1 receptor, one of the five subtypes of dopamine receptors in the brain. This receptor is primarily expressed in the prefrontal cortex, a brain region implicated in cognitive functions such as working memory and decision making. Dysregulation of D1 receptor signaling has been implicated in several neuropsychiatric disorders, including schizophrenia and Parkinson's disease.
In preclinical studies, KNT-127 has been shown to enhance cognitive function and reduce psychotic symptoms in animal models of schizophrenia. It has also been shown to improve motor symptoms in animal models of Parkinson's disease. These findings suggest that KNT-127 may have therapeutic potential in these disorders.
Clinical Development[edit | edit source]
KNT-127 is currently in the early stages of clinical development. Phase I clinical trials have been completed, and the drug has been shown to be safe and well-tolerated in healthy volunteers. Phase II trials are currently underway to evaluate the efficacy of KNT-127 in patients with schizophrenia and Parkinson's disease.
Future Directions[edit | edit source]
If the ongoing clinical trials are successful, KNT-127 could represent a new treatment option for patients with schizophrenia and Parkinson's disease. However, further research is needed to fully understand the therapeutic potential of this compound.
See Also[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
